Hisilicon: Innovative drug HSK51155 tablets have received clinical trial approval notification.

Haiske announced that the company recently received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration. The clinical trial application for HSK51155 tablets, accepted in May 2026, meets the relevant requirements for drug registration and is approved to conduct clinical trials. HSK51155 is an orally administered small molecule analgesic independently developed by the company, intended for the treatment of migraines. In April 2026, the company entered into a cooperation agreement with AbbVie for this project, with a potential total deal amount exceeding $700 million.